Dare Bioscience, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2019. Dare is a clinical-stage women’s health biopharmaceutical company with no approved or commercialized products and no product revenue.
Financial performance and position
| Metric | Q3 2019 | Nine months 2019 | Comparable 2018 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $3.42 million | $10.48 million | $2.62 million and $13.92 million |
| Net loss | $3.39 million | $10.40 million | $2.57 million and $13.82 million |
| Net loss per share | $0.20 | $0.76 | $0.23 and $1.32 |
| Operating cash used | Not separately stated | $9.51 million | $7.56 million |
At September 30, cash and cash equivalents were $2.44 million, down from $6.81 million at year-end 2018. Working capital was approximately $1.4 million; total liabilities were $2.07 million, including $183,196 in operating lease liabilities. The filing does not show a separate borrowing or debt balance. Stockholders’ equity was $1.81 million and accumulated deficit was $40.16 million. Profit margins are not meaningful given the absence of revenue.
Changes versus prior comparable periods
- Q3 net loss increased about $819,000 year over year as operating expenses rose $797,000. R&D increased $520,000, principally for DARE-BV1 and Ovaprene development; G&A increased $144,000, including higher personnel and stock-based compensation costs.
- Nine-month net loss decreased about $3.42 million year over year, largely because 2018 included a $5.19 million goodwill impairment. Excluding that unusual charge, 2019 operating expenses increased as R&D and personnel costs rose.
- Nine-month operating cash use increased about $1.95 million. April 2019’s public offering generated $5.15 million net proceeds and issued 5.26 million shares. The offering also triggered a reduction in certain warrant exercise prices from $3.00 to $0.98 and a $789,594 deemed dividend for common shareholders.
Outlook, developments and risks
- Going concern: Management stated that substantial doubt exists about Dare’s ability to continue as a going concern. It expected existing resources to be insufficient for planned operations through November 2020 and insufficient for at least the next 12 months from issuance without additional capital or significant curtailment. Operating losses and negative cash flows are expected to continue.
- Development plans: Management expected increased expenses through 2020, particularly for planned DARE-BV1 Phase 3, Sildenafil Cream Phase 2b, Ovaprene pivotal effectiveness and safety, and DARE-HRT1 Phase 1 studies. DARE-BV1 Phase 3 was expected to begin in early 2020; the company estimated program costs through its NDA filing at less than $9 million, with a potential filing in late 2020 or early 2021 if studies succeed. These are forward-looking estimates, not assured outcomes.
- Ovaprene: The filing reports positive topline postcoital-test results announced November 12, 2019, after the quarter ended. The small study met its primary endpoint; the company planned to seek an FDA IDE in the first half of 2020 and, subject to FDA review, start a pivotal study in the second half of 2020.
- Microchips transaction: On November 10, 2019, Dare agreed to acquire Microchips Biotech, subject to closing conditions, expected by November 22. The proposed consideration included 3 million Dare shares; Microchips cash was estimated at approximately $5.7 million after transaction expenses. Additional development, sales, royalty and sublicense-based consideration could apply. Dare cautioned that the acquisition was not assured and the expected cash would not fund the current plan for 12 months.
- Capital and listing risks: Dare said it was evaluating financing, grant, collaboration and strategic options; additional equity could dilute shareholders, and financing may not be available on acceptable terms. Its share price had remained below Nasdaq’s $1 minimum bid-price requirement through November 11, with a December 18, 2019 compliance deadline. Equity of $1.81 million was also below the $5 million threshold cited for eligibility for an additional bid-price compliance period.
- Other items: A further $730,722 of NIH grant funding for Ovaprene was contingent on specified requirements and fund availability. The filing reported no material pending legal proceedings and no material changes to previously disclosed risk factors other than the Nasdaq and Microchips risks described above.
Important facts for investors to verify
- Whether Dare raised sufficient capital to fund operations and whether the going-concern uncertainty was resolved.
- Whether the Microchips acquisition closed, its actual cash contribution and the resulting dilution and contingent obligations.
- Nasdaq bid-price and stockholders’ equity compliance status, and any subsequent listing notices or actions.
- FDA decisions, trial initiation and results for DARE-BV1, Ovaprene, Sildenafil Cream and DARE-HRT1, including whether projected timelines and costs changed.
- Cash burn, grant eligibility and receipts, and the timing and potential dilution associated with warrants, financing and license payments.